Dopamine in Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing biochemical and mechanistic pathways without empirical data.
PubMed 34389279 · doi:10.1016/j.cca.2021.08.009
What was done
Narrative review describing dopamine synthesis, receptor subtypes (D1–D5), neuroanatomical distribution, and the biochemical role of dopamine oxidation products in Parkinson's disease pathogenesis based on literature synthesis.
What was found
The abstract reports no numerical data. It reviews mechanistic pathways indicating that dopamine oxidation generates 5,6-indolequinone, dopamine-o-quinone, and aminochrome. Aminochrome stabilizes neurotoxic alpha-synuclein protofibrils, promotes mitochondrial dysfunction and oxidative stress, and impairs protein degradation by lysosomal systems and proteasomes. These neurotoxic effects can be inhibited by preventing polymerization into neuromelanin, reducing aminochrome via DT-diaphorase, or inhibiting monoamine oxidase-catalyzed oxidative deamination.
Why it matters
Synthesizes the biochemical mechanisms through which dopamine metabolism and oxidative intermediates contribute to neurodegeneration in Parkinson's disease, highlighting pathways that may serve as therapeutic targets.
Limits
Narrative review summarizing biochemical mechanisms; reports no primary empirical data, quantitative findings, clinical trials, or systematic search methodology.
Cited by
- context Brainstem dopamine neurons are the only source of dopamine in the brain except for a small pathway in the hypothalamus and pituitary.